On October 22, 2019 Revolution Medicines, Inc., a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways, reported that preclinical in vivo data on the company’s novel inhibitors of oncogenic RAS(ON) mutants will be presented at the 2019 AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) (Press release, Revolution Medicines, OCT 22, 2019, View Source [SID1234542428]). Presented findings will highlight the ability of the company’s inhibitors to overcome adaptive resistance mechanisms and drive xenograft regressions in in vivo models. The 2019 AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) is being held October 26-30, 2019 in Boston, MA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Leveraging its proprietary tri-complex technology platform, Revolution Medicines is developing a portfolio of targeted RAS compounds that it believes are the first potent, mutant-selective, cell-active inhibitors of the active, GTP-bound form of RAS, or RAS(ON). Initially, the company is prioritizing four mutant RAS(ON) targets, KRASG12C, KRASG13C, KRASG12D and NRASG12C.

The data on the company’s active RAS(ON) inhibitors will be reported in podium and poster presentations entitled, "Tri-complex inhibitors of the oncogenic, GTP-bound form of KRASG12C overcome RTK-mediated escape mechanisms and drive tumor regressions in vivo." Details of the presentations are as follows:

Podium Presentation #PR10:

Session: Spotlight on Proffered Papers 3
Presenting Author: Christopher Schulze, Ph.D., senior scientist at Revolution Medicines
Date/Time: Tuesday, October 29, 2019, 12:20 – 12:30 p.m. Eastern
Location: Level 3 Ballroom AB Lobby
Poster Presentation #B077:

Session: Poster Session B: MAPK Pathways 1
Presenting Author: Christopher Schulze, Ph.D., senior scientist at Revolution Medicines
Date/Time: Monday, October 28, 2019, 12:30 – 4:00 p.m. Eastern
Location: Level 2 – Hall D
In addition to the presentations on its mutant RAS inhibitors, Revolution Medicines will also report preclinical data from its 4EBP1/mTORC1 program in a poster presentation at the conference. The presented findings will highlight results of the company’s work in identifying a potential biomarker of response to selective mTORC1 inhibitors. Details of that presentation are as follows:

Poster Presentation #B108:

Title: 4EBP3 mRNA as a biomarker of therapeutic response to treatment with mTORC1 inhibitors
Presenting Author: Bianca Lee, Ph.D., scientist at Revolution Medicines
Session: Poster Session B: mTOR/PI3-Kinase
Date/Time: Monday, October 28, 2019, 12:30 – 4:00 p.m. Eastern
Location: Level 2 – Hall D